This page compares ibogaine and 5-MeO-DMT across mechanism, clinical evidence, safety, access, and patient profile. Both are under active research as potential treatments for addiction and mental health conditions, yet they differ substantially in origin, duration, and risk profile.

At a Glance

Criterion Ibogaine 5-MeO-DMT
Primary Source Tabernanthe iboga plant (Central Africa) Bufo alvarius toad secretion; synthetic production
Mechanism Multi-target: NMDA antagonist, kappa/mu opioid agonist, sigma-2 receptor, serotonin reuptake inhibition, GDNF/BDNF upregulation Potent 5-HT1A and 5-HT2A/2C agonist; sigma-1 receptor activity
Experience Duration 12–36 hours 15–45 minutes (smoked/vaporized); up to 90 min (intramuscular)
Evidence Level Observational studies, case series, Phase 2 trials ongoing; strongest data in opioid use disorder Pilot studies, observational data; Phase 2 trials for depression/PTSD ongoing
Legal Status (US) Schedule I federal; legal in some states (Utah for research) Schedule I federal; not state-level exempted
Global Access Legal clinics in Mexico, Costa Rica, Portugal, Gabon Legal/tolerated in Mexico, Jamaica, some retreat settings
Typical Cost $5,000–$15,000+ per session $1,500–$5,000 per session
Cardiac Risk High — QT prolongation, arrhythmia risk; fatalities documented Lower — but hypertension, serotonin syndrome possible
Best-Studied For Opioid use disorder, alcohol use disorder, PTSD Depression, anxiety, existential distress, PTSD

⚠️ Ibogaine carries serious cardiac risks and has caused fatalities. Medical supervision and pre-treatment cardiac screening required.

Mechanism of Action

Ibogaine and 5-MeO-DMT act on the brain through fundamentally different pharmacological pathways, which helps explain why their experiential and therapeutic profiles diverge so sharply.

Ibogaine is pharmacologically complex. It acts as an antagonist at NMDA glutamate receptors, an agonist at kappa and mu opioid receptors, inhibits the reuptake of serotonin, dopamine, and norepinephrine, and binds sigma-2 receptors. Its active metabolite, noribogaine, has a long half-life (28–49 hours) and sustains opioid receptor activity well after the primary experience ends. Crucially, ibogaine upregulates glial cell line-derived neurotrophic factor (GDNF) and brain-derived neurotrophic factor (BDNF), which researchers believe drives neuroplasticity and may underlie its documented capacity to interrupt opioid withdrawal and reduce cravings. This multi-receptor profile also contributes to its cardiac risk: ibogaine blocks hERG potassium channels, prolonging the cardiac QT interval.

5-MeO-DMT (5-methoxy-N,N-dimethyltryptamine) is a tryptamine that acts primarily as a potent agonist at serotonin 5-HT1A and 5-HT2A receptors, with additional activity at sigma-1 receptors. Its 5-HT1A affinity is notably higher than that of other classic psychedelics such as psilocybin, which may account for its distinctive phenomenology — often described as a dissolution of self-referential processing rather than the visually complex experiences associated with psilocybin or LSD. Preclinical research suggests 5-MeO-DMT also promotes neuroplasticity, including dendritic growth and synaptogenesis, though human mechanistic studies remain limited compared to psilocybin.

In summary, ibogaine's polypharmacology makes it uniquely suited to interrupting opioid dependence but also uniquely dangerous. 5-MeO-DMT's focused serotonergic action produces intense but shorter-duration experiences with a comparatively more manageable physiological risk profile.

Clinical Evidence

Neither substance has completed Phase 3 randomized controlled trials as of 2026, placing both in the category of promising but not yet fully validated treatments.

Ibogaine has the longer research history. A landmark observational study published in Nature Medicine (2023) examined 30 Special Operations veterans who received ibogaine treatment in Mexico and reported significant reductions in PTSD symptoms, depression, anxiety, and disability at one-month follow-up, with no serious adverse events in that screened cohort. Earlier observational work by Noller et al. (2018) documented reductions in opioid withdrawal severity and cravings. Multiple Phase 2 trials are currently recruiting in the US and Europe, particularly for opioid use disorder and alcohol use disorder. The evidence base is largest for opioid use disorder, where ibogaine's capacity to acutely suppress withdrawal and reduce cravings after a single session is relatively well-documented, though long-term relapse data remain mixed.

5-MeO-DMT has a smaller but growing evidence base. A prospective observational study by Uthaug et al. (2019) found significant reductions in depression and anxiety ratings following ceremonial 5-MeO-DMT use, with effects persisting at four-week follow-up. A 2022 survey study by Davis et al. found high rates of self-reported improvements in depression, anxiety, PTSD, and substance use among past users. Pilot clinical trials evaluating synthetic 5-MeO-DMT for treatment-resistant depression and PTSD are underway, with several sponsored by biotech companies including Beckley Psytech and GH Research. Compared to ibogaine, the controlled clinical data are more nascent, and the patient populations studied have largely been psychologically healthy volunteers or self-selecting retreat participants rather than clinical populations.

Neither treatment has regulatory approval in any jurisdiction for any psychiatric indication. Ibogaine's evidence base for opioid use disorder is currently the more clinically detailed of the two.

Safety and Risks

Safety profiles differ substantially and are a primary practical consideration when comparing these two substances.

Ibogaine carries well-documented cardiac risks. It prolongs the QT interval by blocking hERG cardiac potassium channels, which can precipitate potentially fatal arrhythmias including ventricular tachycardia (torsades de pointes). A review of ibogaine-associated fatalities identified cardiac events, interactions with concurrent drug use (especially opioids), and pre-existing cardiac conditions as primary risk factors. Reputable clinics require 12-lead ECG screening, electrolyte panels, and medication washout protocols before treatment. Contraindications include a history of cardiac arrhythmia, prolonged QT interval, and use of QT-prolonging medications. The long duration of the experience (up to 36 hours) also places physical demands on patients, particularly regarding hydration and rest. Psychological risks include intense, emotionally confronting content that can be destabilizing without adequate preparation and integration support.

5-MeO-DMT poses fewer cardiac risks, though its serotonergic potency introduces other concerns. The primary physiological risks include acute hypertension, tachycardia, and — when combined with serotonergic medications or other substances — potentially serious serotonin syndrome. Because the experience is extremely rapid in onset and profoundly disorienting, physical safety during the session (falls, aspiration) is a real consideration requiring competent facilitation. The psychological intensity of 5-MeO-DMT is not necessarily lower than ibogaine; many participants report the experience as among the most overwhelming of their lives. Cases of persistent psychological disturbance, including anxiety and derealization following poorly supported sessions, have been documented in survey and case literature. Screening for personal or family history of psychosis is standard practice.

Both substances require careful screening and experienced facilitation. Ibogaine's cardiac risk elevates the stakes of inadequate medical preparation substantially.

⚠️ Ibogaine carries serious cardiac risks and has caused fatalities. Medical supervision and pre-treatment cardiac screening required.

Cost and Access

Practical access to both substances is constrained by their Schedule I federal status in the US and many other jurisdictions, funneling patients toward international retreat and clinic settings.

Ibogaine treatment is primarily accessed through licensed clinics in Mexico (particularly Tijuana and Puerto Vallarta), Costa Rica, and Portugal, where it is legal or operating within regulatory frameworks. A medically supervised single-session treatment with pre- and post-care typically costs between $5,000 and $15,000 USD. Some higher-end clinics offering intensive post-treatment integration and extended stays can exceed $20,000. Utah passed legislation in 2024 creating a pathway for supervised ibogaine therapy in state-licensed facilities, though implementation is ongoing. Access is further limited by the requirement for thorough medical preparation, which adds time and out-of-pocket cost before travel.

5-MeO-DMT retreats and sessions are available in Mexico (where it is legal), Jamaica, and through various international facilitators. Costs are generally lower, ranging from approximately $1,500 to $5,000 per session, partly reflecting the shorter facilitation time required. Synthetic 5-MeO-DMT (e.g., from pharmaceutical-grade production) is increasingly preferred over toad-derived material due to supply consistency, animal welfare concerns, and the risk of contamination in wild-harvested secretions from Bufo alvarius toads. Access to clinical trials for both substances is possible in the US and Europe for eligible patients, typically at no cost, through ClinicalTrials.gov or equivalent registries.

Who Each Treatment May Suit

Patient profiles, goals, and medical histories influence which — if either — substance might be considered.

Ibogaine is most frequently sought by individuals with opioid use disorder, particularly those who have cycled through conventional treatments (methadone, buprenorphine, naltrexone) without sustained success. Its documented ability to substantially attenuate acute opioid withdrawal within hours is a unique feature not replicated by other psychedelic approaches. It is also pursued for alcohol use disorder, stimulant use disorders, PTSD, and treatment-resistant depression. It is not suitable for individuals with cardiac arrhythmias, prolonged QT intervals, significant cardiovascular disease, severe liver disease, or those currently taking QT-prolonging or serotonergic medications without a sufficient washout. The long duration demands physical stamina and willingness to undergo intensive medical screening.

5-MeO-DMT is more frequently sought by individuals pursuing rapid resolution of depression, anxiety, existential distress, or seeking profound experiences reported to catalyze perspective shifts. Its brief duration makes it more logistically accessible and less physically demanding. It may be considered by individuals who are not candidates for longer psychedelic sessions. It is contraindicated for those with a personal or family history of psychosis or schizophrenia spectrum disorders, those taking MAOIs or serotonergic medications without washout, and those with significant cardiovascular instability. People who have found psilocybin or ketamine sessions insufficiently impactful sometimes pursue 5-MeO-DMT for its reported intensity.

Key Difference

The central distinction between ibogaine and 5-MeO-DMT lies not in their therapeutic intentions — both are investigated for mental health and addiction — but in their pharmacological architecture and the experiences they produce. Ibogaine is a prolonged, biologically complex intervention with a uniquely strong signal in opioid use disorder and a correspondingly serious cardiac risk profile that necessitates medical infrastructure. 5-MeO-DMT is a brief, serotonergically focused experience with a lower physiological risk threshold and emerging evidence across depressive and anxiety conditions, but without ibogaine's breadth of mechanistic action on opioid pathways. These differences make them less competing options than distinct tools with partially overlapping but meaningfully different candidate populations.

Frequently Asked Questions

Some retreat programs offer sequential protocols — typically ibogaine first, followed by 5-MeO-DMT one to several days later — based on clinical observation that the combination may deepen integration. However, this practice is not validated by controlled research. The combination carries additive serotonergic risks and requires careful timing and medical oversight. No published clinical trials have evaluated this protocol, and individuals considering it should seek facilities with documented experience and robust medical monitoring.
The current evidence strongly favors ibogaine for opioid use disorder. Its opioid receptor activity and GDNF upregulation appear to directly address the neurobiological mechanisms of opioid dependence, and multiple observational studies document acute suppression of withdrawal and sustained reduction in cravings. 5-MeO-DMT has not been specifically studied in opioid use disorder populations to a comparable degree, and its mechanism does not include direct opioid receptor activity.
Ibogaine typically produces a prolonged experience characterized by vivid, often autobiographical visions — sometimes described as a "life review" — alongside intense introspective content. Physical symptoms including nausea, ataxia, and sensitivity to light and sound are common. 5-MeO-DMT produces an extremely rapid and often overwhelming dissolution of ordinary self-perception, sometimes described as ego dissolution or a sense of unity with consciousness. It is generally less visually complex than ibogaine and more phenomenologically characterized by a loss of boundaries. Both can be profoundly difficult and profoundly meaningful; the character of difficulty differs considerably.
In terms of physiological risk for medically screened, healthy individuals, 5-MeO-DMT has a more favorable cardiac safety profile than ibogaine. Ibogaine's hERG channel blockade and QT prolongation create a genuine risk of fatal arrhythmia even in adequately screened patients, though this risk is substantially reduced by thorough cardiac workup. Neither is without psychological risk: both can produce intensely destabilizing experiences, and both require competent facilitation and integration support. Risk comparisons are highly dependent on the individual's medical history and the quality of the setting.
Ibogaine has a broad list of contraindicated medications including QT-prolonging drugs (certain antidepressants, antipsychotics, antibiotics, and antiarrhythmics), MAOIs, stimulants, opioids, and lithium. The washout requirements vary by medication and half-life. 5-MeO-DMT is contraindicated with MAOIs (risk of serotonin syndrome), SSRIs, SNRIs, and other serotonergic agents. Both substances require individualized medication review by a knowledgeable clinician. This is not an exhaustive list — always consult a qualified healthcare provider before considering either treatment.
Both remain Schedule I controlled substances at the federal level. Utah passed legislation enabling supervised ibogaine therapy in licensed facilities, though the regulatory infrastructure is still being developed. Neither substance is currently available through state-licensed commercial programs in the way that ketamine (as a prescription medication) is. Access within the US is currently through approved clinical trials. Individuals typically seek treatment at international clinics in countries where one or both substances are legal or unscheduled.
Integration — the process of working with and applying insights from the psychedelic experience — is considered clinically important for both substances. For ibogaine, where the experience can last over a day and surface highly personal material, structured integration with a therapist or counselor is widely regarded as important for translating the acute experience into lasting behavioral change. For 5-MeO-DMT, the experience's intensity and the challenge of articulating or making sense of non-ordinary states makes integration equally important, even though the session itself is brief. Research consistently suggests that outcomes correlate with the quality of preparation and integration support, not only the substance administered.

Informational only. Not medical or legal advice. Ibogaine is Schedule I in the US. Consult qualified professionals before considering treatment.